EVT Evotec SE

DGAP-News: EVOTEC SE TO ANNOUNCE RESULTS FOR THE FIRST NINE MONTHS 2021 ON 11 NOVEMBER 2021

DGAP-News: Evotec SE / Key word(s): Miscellaneous
EVOTEC SE TO ANNOUNCE RESULTS FOR THE FIRST NINE MONTHS 2021 ON 11 NOVEMBER 2021

03.11.2021 / 14:08
The issuer is solely responsible for the content of this announcement.

 

Hamburg, Germany, 03 November 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will announce its financial results for the first nine months 2021 on Thursday, 11 November 2021.

The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.

Conference call details
Date: Thursday, 11 November 2021
Time: 02.00 pm CET (08.00 am ET, 01.00 pm GMT)

From Germany: 220
From France:
From Italy: 3
From Switzerland:
From UK: 0
From USA:
Access Code: 82123163#

A simultaneous slide presentation for participants dialling in via phone is available at .


Webcast details

To join the audio webcast and to access the presentation slides you will find a link on our homepage shortly before the event.

A replay of the conference call will be available for seven days and can be accessed from Germany by dialling 1, from UK by dialling 0 and from USA by dialling +1 (844) 307-9362.

The access code is 315614529#. The on-demand version of the webcast will be available on our website: and under the direct link .


About Evotec SE

Evotec is an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry. Evotec's mission is to discover best and first-in-class medicines for a broad range of difficult to treat diseases in collaboration with our partners. Evotec has built a comprehensive suite of fully integrated, next generation technology platforms which it believes will transform the way new drugs are discovered. By leveraging the advanced capabilities of Evotec's integrated platforms, Evotec is able to provide solutions to its partners that enable significant improvements in the quality of new drugs while accelerating the drug discovery process and reducing the high cost of attrition often associated with traditional drug discovery processes.

FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Among the factors that may result in differences include risks indicated in the risk factors included in Evotec's Registration Statement on Form F-1 and other filings with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
 

INVESTOR RELATIONS CONTACT:
,
T. +49.(0)40.560 81-775
F. +49.(0)40.560 81-333


03.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: Evotec SE
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail:
Internet:
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1245741

 
End of News DGAP News Service

1245741  03.11.2021 

fncls.ssp?fn=show_t_gif&application_id=1245741&application_name=news&site_id=research_pool
EN
03/11/2021

Underlying

EVTEvotec SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Evotec SE

Free Trial
EVT EVOTEC SE

Evotec SE: 2 directors

Two Directors at Evotec SE sold/bought 36,000 shares at between 5.156EUR and 5.160EUR. The significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...

18h / 49m 18h / 49m 1 EN
Thomas J. Schiessle
  • Thomas J. Schiessle
EUR 290.00
EVT EVOTEC SE

Schwache Konjunktur verzögert weiterhin „Profitability Restart“ - Mone...

Q3/25-KPIs zeigen eine Umsatz- und EBITDA Margen-Verschlechterung (Umsatz -11% YoY auf € 164 Mio./Marge: -9,17 %; EPS € -0,24), doch sind diese durch Phasing-Effekte und Reset-Einsparungen überzeichnet. Die anhaltend schwache Nachfrage im Markt für frühe Arzneimittelforschung (D&PD) konnte das gut gelaufene Geschäft von Just-Evotec Biologics (JEB) nur teilweise ausgleichen. Zudem kämpft Evotec mit Unterauslastung. Hinzu kommen Kosten im Zusammenhang mit dem Anlaufen der JEB-Anlage im französisch...

11/07/25 November 7, 2025 5 DE
Thomas J. Schiessle
  • Thomas J. Schiessle
EUR 290.00
EVT EVOTEC SE

Weak economic conditions continue to delay the 'Profitability Restart'...

Q3/25 KPIs show a decline in revenue and EBITDA margins (revenue -11% YoY to €164m / margin: -9.17%; EPS € -0.24), but these are exaggerated due to phasing effects and reset savings. The persistently weak demand in the early drug discovery (D&PD) market could only partially offset the well-performing business of Just-Evotec Biologics (JEB). Additionally, Evotec is struggling with underutilization. There are also costs associated with the start-up of the JEB facility in Toulouse, France, which is...

11/07/25 November 7, 2025 4 EN
Roy Külter ... (+2)
  • Roy Külter
  • Steven Boumans
CRI CHARGEURS SA
BVI BUREAU VERITAS SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
EVT EVOTEC SE
TNG TRANSGENE SA
ISS ISS A/S
ITRK INTERTEK GROUP PLC
BOSS HUGO BOSS AG
ACX ACERINOX SA
TRI TRIGANO SA
FAE FAES FARMA S.A.
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
ROYAL VOPAK NV
MONT MONTEA SCA
BPOST BPOST SA
CPINV CARE PROPERTY INVEST SA
TWEKA TKH GROUP N.V. CERT
DGM DIAGNOSTIC MEDICAL SYSTEMS
RUI RUBIS SCA
DIGI DIGI COMMUNICATIONS NV
GEST GESTAMP AUTOMOCION S.A.
ALFEN ALFEN NV
HFG HELLOFRESH SE
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
AG1 AUTO1 GROUP
SGSN SGS SA
SHA SCHAEFFLER AG
11/05/25 November 5, 2025 1 EN
Roy Külter ... (+2)
  • Roy Külter
  • Steven Boumans
CRI CHARGEURS SA
BVI BUREAU VERITAS SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
EVT EVOTEC SE
TNG TRANSGENE SA
ISS ISS A/S
ITRK INTERTEK GROUP PLC
BOSS HUGO BOSS AG
ACX ACERINOX SA
TRI TRIGANO SA
FAE FAES FARMA S.A.
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
ROYAL VOPAK NV
MONT MONTEA SCA
BPOST BPOST SA
CPINV CARE PROPERTY INVEST SA
TWEKA TKH GROUP N.V. CERT
DGM DIAGNOSTIC MEDICAL SYSTEMS
RUI RUBIS SCA
DIGI DIGI COMMUNICATIONS NV
GEST GESTAMP AUTOMOCION S.A.
ALFEN ALFEN NV
HFG HELLOFRESH SE
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
AG1 AUTO1 GROUP
SGSN SGS SA
SHA SCHAEFFLER AG
11/05/25 November 5, 2025 1 FR

ResearchPool Subscriptions

Get the most out of your insights

Get in touch